Wenying Chai

USPTO Granted Patents = 31 (Patent Applications = 11)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 72(Granted Patents)

Company Filing History:

24 out of 2,076

Janssen Pharmaceutica Nv

patents

4 out of 363

Ortho-mcneil Pharmaceutical Corp.

patents

1 out of 32

Janssen Pharmaceutica

patents

4. 1 out of 1

Ortho-mcneil Phamraceutical, Inc.

patent

5. 1 out of 13

Johnson & Johnson Pharmaceutical Research & Development, LLC

patents

Years Active: 2001-2025

Loading Chart...

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12378254 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2025-08-05),

2. 11897900 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2024-02-13),

3. 11827638 - Imidazopyrrolopyridine as inhibitors of the JAK family of kinases (2023-11-28),

4. 11667644 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2023-06-06),

5. 11427601 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2022-08-30),

6. 11254673 - Small molecule inhibitors of NF-κB inducing kinase (2022-02-22),

7. RE48841 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2021-12-06),

8. 11059828 - Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators (2021-07-13),

9. 10981911 - Imidazopyrrolopyridine as inhibitors of the JAK family of kinases (2021-04-20),

10. 10947252 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2021-03-16),

11. 10172856 - 2,4-diaminopyrimidine derivatives as histamine H4 modulators (2019-01-08),

12. 9981909 - Serotonin receptor modulators (2018-05-29),

13. 9695149 - 1,2,6-substituted benzimidazoles as flap modulators (2017-07-04),

14. 9682972 - 1,2,5-substituted benzimidazoles as flap modulators (2017-06-20),

15. 9682971 - 1,2,5-Substituted benzimidazoles as flap modulators (2017-06-20),

Title: Wenying Chai: Innovator in Pharmaceutical Patents

Introduction: Wenying Chai, located in San Diego, CA, is a distinguished inventor with a remarkable portfolio of 30 patents. His work primarily focuses on developing innovative pharmaceutical solutions aimed at treating complex medical conditions.

Latest Patents: Among Wenying Chai's latest patents are groundbreaking inventions such as "Inhibitors of KEAP1-Nrf2 protein-protein interaction." This includes sultam compounds, pharmaceutical compositions containing them, and methods for using these compounds to treat diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. Another notable patent is related to "Imidazopyrrolopyridine as inhibitors of the JAK family of kinases." This invention encompasses specific compounds and methods to address conditions mediated by JAK, particularly inflammatory bowel disease.

Career Highlights: Wenying Chai has enriched his professional experience through significant roles at esteemed companies in the pharmaceutical industry such as Janssen Pharmaceutica and Ortho-McNeil Pharmaceutical Corporation. His contributions have been pivotal in promoting health solutions that address pressing medical issues.

Collaborations: Throughout his career, Wenying has collaborated with notable professionals in the field, including Curt A. Dvorak and Paul J. Krawczuk. These collaborations have facilitated the development of impactful innovations that aim to enhance patient outcomes.

Conclusion: Wenying Chai stands out as a prominent figure in the field of pharmaceuticals, with his innovative patents and collaborations demonstrating a commitment to advancing medical science. His work continues to hold promise for the treatment of various diseases, affirming his role as a leading inventor in the industry.

This text is generated by artificial intelligence and may not be accurate.